This site is intended for healthcare professionals

Keytruda significantly improved PFS compared with brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma. - Merck Inc.

Read time: 1 mins
Published:3rd Mar 2020
Condition: Hodgkin Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest